Carcinoid syndrome is the aftermath which occurs after carcinoid tumors. Signs of the
syndrome include unexplained weight gain, sweating, fast heartbeat, intestinal bleeding,
vasoconstriction, and shortness of breath. A combination of palliative and supportive care is
required for controlling the syndrome. Market Research Future (MRFR) outlines various trends
and opportunities in the global carcinoid syndrome management market which estimate an
accurate market valuation.
Request Sample Copy:
The global carcinoid syndrome management market is poised for a meteoric valuation with a
high growth rate between 2017 and 2022 (forecast period). Rising incidence of hormonal
disorders, high levels of carcinogens, and unbreakable smoking habits are factors which can
drive the market growth. As per the National Institute of Health, incidence of carcinoid tumor is
reportedly 2 for every 100,000 with the possibility of tumor in the gastrointestinal (GI) tract.
Surgical options for removal or elimination of carcinoid tumors can also be one of the biggest
drivers of the market.
Paucity of approved drugs and vaccines for controlling the disease can be the only restraining
factor in the market.
The carcinoid syndrome management market is segmented by organs affected by the disease,
treatment, and end-user.
By organs affected by the disease, it is segmented into liver, pancreas, stomach, colon,
appendix, lungs, rectum, small intestine, and others. The small intestine segment accounted for
40% share followed by rectum at 14% share in 2017.
By treatment, it is segmented into hepatic artery embolization agents, biological therapy, and
chemotherapy. Chemotherapy is projected to gain a large market share due to being the first
line of treatment for cancers. Bu hepatic artery embolization agents are gaining traction and
may contribute to overall market revenue. This can be attributed to awareness of carcino